Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer

BACKGROUND: Phosphatidylinositol-3-kinase (PI3K) and androgen receptor pathway activation is common in metastatic castration resistant prostate cancer (mCRPC). Buparlisib is an oral, pan-class I PI3 kinase inhibitor. METHODS: This was a multisite single arm phase II trial of buparlisib 100 mg ± enza...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Eur J Cancer
Main Authors: Armstrong, Andrew J., Halabi, Susan, Healy, Patrick, Alumkal, Joshi J., Winters, Carolyn, Kephart, Julie, Bitting, Rhonda L., Hobbs, Carey, Soleau, Colleen F., Beer, Tomasz M., Slottke, Rachel, Mundy, Kelly, Yu, Evan Y., George, Daniel J.
Format: Artigo
Sprog:Inglês
Udgivet: 2017
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6345641/
https://ncbi.nlm.nih.gov/pubmed/28502694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2017.02.030
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker